Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma

World Journal of Hepatology

Volumn 7, Issue 3, 2015, Pages 628-632

  Scaffaro, Leandro Armani ^a   Stella, Steffan Frosi ^b   Alvares Da Silva, Mario Reis ^a   Kruel, Cleber Dario Pinto ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b National Institute of Science and Technology for Health Technology Assessment (IATS)   (Brazil)

Author keywords

Barcelona clinic liver cancer; Hepatocellular carcinoma; Subclassification; Transarterial embolization

Indexed keywords

EID: 84928963678     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i3.628     Document Type: Article

References (13)

1. Tsochatzis EA, Fatourou E, O'Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20: 3069-3077 [PMID: 24695579 DOI: 10.3748/wjg.v20.i12.3069]
2. Sangro B. [Survival benefit with intraarterial techniques in hepatocellular carcinoma]. Gastroenterol Hepatol 2014; 37 Suppl 2: 95-101 [PMID:25087719 DOI: 10.1016/S0210-5705(14)70076-7]
3. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X]
4. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52 [PMID: 19908093 DOI: 10.1007/s00270-009-9711-7]
5. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12: 321-326 [PMID:11287509 DOI: 10.1016/S1051-0443(07)61911-3]
6. Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013; 108: 1252-1259 [PMID: 23449352 DOI: 10.1038/bjc.2013.85]
7. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25 [PMID:17103105 DOI: 10.1007/s00270-006-0062-3]
8. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348-359 [PMID: 23397536 DOI: 10.1055/ s-0032-1329906]
9. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI:10.1002/hep.24199]
10. Piscaglia F, Terzi E, Cucchetti A, Trimarchi C, Granito A, Leoni S, Marinelli S, Pini P, Bolondi L. Treatment of hepatocellular carcinoma in Child-Pugh B patients. Dig Liver Dis 2013; 45:852-858 [PMID: 23582346 DOI: 10.1016/j.dld.2013.03.002]
11. Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, Marinis A, Kelekis A, Alexopoulou E, Chatziioannou A, Chatzimichael K, Dourakis S, Kelekis N, Rizos S, Kelekis D. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012; 35: 1119-1128 [PMID:22614031 DOI: 10.1007/s00270-012-0394-0]
12. Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol 2014; 29: 787-793 [PMID: 24224567 DOI: 10.1111/jgh.12452]
13. Wang JH, Kee KM, Lin CY, Hung CH, Chen CH, Lee CM, Lu SN. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol 2015; 30: 358-363 [PMID: 25088668 DOI:10.1111/jgh.12686]